Drug Profile
Research programme: protein secretion therapeutics - Kezar Life Sciences
Alternative Names: KZR-8834Latest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Kezar Life Sciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Membrane transport protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Cancer in USA
- 28 Jul 2019 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 20 Apr 2019 Pharmacodynamics data from a preclinical trial in Multiple myeloma presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)